China Dog Scratch Rabies Vaccine For Human Protection Manufacturer, Supplier, Factory

As a trusted China manufacturer and global exporter, AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. delivers premium Dog Scratch Rabies Vaccine For Human Protection, a specialized inactivated Vero cell vaccine tailored exclusively for post-exposure prophylaxis against minor and moderate dog scratch injuries. Unlike conventional rabies vaccines focused solely on severe bite wounds, this formulation optimizes immune response for superficial skin abrasions caused by canine contact, boasting 36-month ultra-long shelf life, zero preservative formula and stable high seroconversion rate, serving daily public health safety protection for global individuals and medical institutions.Most people underestimate the health risks hidden behind trivial dog scratches. In global rabies epidemic statistics, a large number of clinical infection cases originate from untreated minor scratch wounds, where rabies virus invades the human body through damaged skin and causes latent fatal infection. Dog Scratch Rabies Vaccine is professionally developed to fill this public health prevention gap. Produced in strict accordance with national drug standards and GMP workshop specifications by AIM Honor (Ningbo) Biopharmaceutical Co., Ltd., this freeze-dried human rabies vaccine abandons excessive immune stimulation design, adopts gentle and efficient antigen activation technology, and becomes the most suitable preventive biological product for daily canine scratch exposure encountered by pet practitioners, residents and outdoor workers worldwide.

Product Background & Definition

Rabies remains one of the most dangerous infectious diseases across continents. Once clinical symptoms emerge, survival possibility is extremely limited. Many emergency vaccination plans are designed targeting deep, bleeding bite injuries, while mild epidermal scratches are continuously ignored by exposed populations. This creates a persistent blind spot in grassroots epidemic prevention work.

Dog Scratch Rabies Vaccine For Human Protection is an inactivated freeze-dried vaccine based on mature Vero cell culture technology. It delivers targeted immune stimulation to cope with exposure scenarios brought by dog scratches, whether the abrasion generates visible bleeding or only broken outer skin layers. The production framework draws on decades of strain research experience from AIM vaccine research laboratories, maintaining consistent antigen activity in every production batch to support reliable post-exposure protection.

Immunization Working Principle

When dog claws break human skin, saliva carrying rabies virus may stay on wound surfaces and gradually migrate toward peripheral nerve tissue. Waiting for obvious discomfort or wound inflammation greatly raises infection risks. Timely inoculation activates the human immune system to build an effective defense barrier.

1. Antigen recognition: Purified inactivated rabies virus antigen prompts immune cells to identify threatening pathogens without triggering live virus infection risks.

2. Neutralizing antibody generation: The body continuously produces targeted antibodies capable of binding and clearing invading rabies virus before it reaches the central nervous system.

3. Long-term immune memory: After completing the full vaccination series, immune memory cells remain active inside the human body, supporting sustained protection within months after inoculation.

For low-grade exposure such as dog scratches, the balanced immune intensity of Dog Scratch Rabies Vaccine avoids excessive bodily reactions while reaching the antibody threshold required by WHO international prevention standards.

Technical Specification Sheet

All test indicators listed above follow unified detection standards implemented in the factory quality control laboratory. Bulk buyers such as medical distributors and disease control institutions can obtain complete batch testing reports for customs clearance and tender document submission upon request.

Distinct Competitive Advantages

Many generic rabies vaccines on the market are formulated for severe trauma exposure. Dog Scratch Rabies Vaccine For Human Protection carries optimized characteristics that fit mild injury prevention scenarios, bringing tangible benefits to medical operators and end recipients.

● Gentle immune response: No extra preservatives or bovine serum added during manufacturing. The probability of local swelling, fever and other adverse reactions stays within a controllable range, and most mild discomfort disappears naturally within 48 hours without special treatment.

● Stable batch consistency: Automated closed bioreactor production reduces manual intervention. Every batch undergoes multiple rounds of activity testing to avoid large quality fluctuations between different production cycles.

● Flexible immunization compatibility: The vaccine supports standard 5-dose vaccination schedules and can adapt to the WHO recognized 4-dose simplified procedure, convenient for hospitals with diversified clinical service demands.

● Sustainable bulk supply: Supported by the large-scale production base in Ningbo, the factory can fulfill continuous large orders for public health projects in rabies high-incidence regions across Asia, Africa and Latin America.

Applicable Occasions & Groups

Scratch injuries by dogs happen in countless daily scenarios. This vaccine provides reliable emergency protection for all exposed groups without unreasonable population restrictions.

1. Ordinary residents including children, adults and seniors who suffer accidental dog scratches at home or in public areas.

2. Pet industry practitioners including groomers, breeding staff, animal rescue volunteers and veterinary clinic employees with frequent canine contact risks.

3. Pregnant women and breastfeeding individuals exposed to dog scratch injuries. Considering the extremely high fatality risk of rabies infection, timely vaccination is strongly recommended regardless of physiological status.

4. Field workers, long-term travelers and expatriates staying in areas with uncontrolled stray dog populations and limited local medical resources.

5. People with stable mild chronic conditions who encounter skin abrasions caused by dog claws.

Only individuals with confirmed severe hypersensitivity to vaccine ingredients are not suitable for inoculation. For all other exposed people, Dog Scratch Rabies Vaccine serves as the primary choice for post-exposure emergency prevention.

Quality Control & Factory Credentials

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. operates full production lines certified under GMP specifications. Every production link, from cell cultivation, virus inoculation, inactivation, freeze-drying to finished product packaging, follows standardized operating procedures.

The internal quality inspection department conducts independent sampling testing before any batch leaves the factory. Complete documentation including batch release certificates, product specification files and qualification forms can be provided for overseas import customs procedures. The enterprise maintains long-term product export experience, delivering biological products to more than 20 countries around the globe.

Frequently Asked Questions

Q1: Do I need rabies vaccine for non-bleeding dog scratches?

A1: Vaccination recommendation relies on skin integrity. Once the epidermis is broken and contacts dog saliva, rabies virus may invade the body. Even minor scratches without visible bleeding belong to exposure risk. Timely post-exposure vaccination is the most reliable preventive measure. Dog Scratch Rabies Vaccine For Human Protection is developed specifically for such mild scratch exposure scenarios.

Q2: Is it too late to get vaccinated after 24 hours of exposure?

A2: There is no rigid 24-hour deadline for post-exposure vaccination. Vaccination should start immediately as soon as possible. Even if several days or weeks have passed after dog scratch exposure, completing the full vaccination series can still effectively prevent rabies onset as long as clinical symptoms have not appeared.

Q3: Can pregnant or lactating women receive this rabies vaccine?

A3: Yes. This is an inactivated vaccine without live virus. Mass clinical data proves it brings no extra risks to pregnant women, fetuses or breastfeeding infants. Since rabies has nearly 100% mortality, exposed pregnant and lactating people are advised to complete vaccination without delay.

Q4: What common adverse reactions may occur after vaccination?

A4: Mild local reactions including injection site pain, redness and swelling may occur. A small number of recipients experience transient low-grade fever, fatigue and headache. These symptoms usually resolve within 1–2 days naturally. Severe allergic reactions are extremely rare. Seek immediate medical help if abnormal discomfort persists.

Q5: What storage requirements must be followed during transportation and storage?

A5: Constant temperature between 2℃ and 8℃ must be maintained continuously. Freezing will permanently damage vaccine activity. Direct sunlight should be avoided. All cold chain transport needs complete temperature tracking records for inspection by customs and health authorities.

Q6: Can this vaccine be used for pre-exposure prophylaxis?

A6: Yes. Besides emergency use after dog scratch exposure, the vaccine can also be applied for pre-exposure immunization for high-risk groups such as animal rescue staff, veterinarians and people staying long-term in rabies endemic zones.

Q7: Is there any difference between vaccine for dog bites and vaccine for dog scratches?

A7: The core antigen potency meets identical international standards. Dog Scratch Rabies Vaccine For Human Protection is clinically optimized for mild epidermal exposure such as scratches, with milder immune stimulation and higher acceptance for daily public prevention scenarios.

Cooperation & Procurement Support

The factory accepts formal bulk orders for medical distributors, community health centers, national disease control projects and international pharmaceutical trading companies. Our overseas business team provides standardized cold chain packaging plans, export document guidance and technical data sheets. We support negotiation on order volume and delivery timeline for emergency public health procurement demands. Send your detailed purchasing requirements to obtain factory quotations and supporting qualification materials.